Adalimumab - StatPearls - NCBI Bookshelf
2023年11月12日 · Mechanism of Action. Adalimumab is a fully human, recombinant immunoglobulin G (IgG) anti-TNF-α mAb with high affinity. Adalimumab consists of 1330 amino acids and has a molecular weight of approximately 148 kDa. The mechanism of action of adalimumab involves the inhibition of the binding of TNF-α to its receptor, affecting both the …
Adalimumab - Wikipedia
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Adalimumab: Uses, Interactions, Mechanism of Action
Mechanism of action. Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors.
The First WHO International Standard for Adalimumab: Dual Role …
Adalimumab (Humira ®), the world’s first fully human IgG1 therapeutic monoclonal antibody (mAb), produced using phage display technology made history when initially approved for treatment of moderate-to-severe forms of rheumatoid arthritis (RA) in 2002 and 2003 by FDA and EMA respectively (1).
Adalimumab - PubMed
This activity comprehensively reviews the indications, mechanism of action, administration, potential adverse effects, and contraindications of adalimumab, providing the interprofessional healthcare team with the necessary information to effectively utilize the drug and treat certain autoimmune conditions.
Tumor Necrosis Factor Inhibitors - StatPearls - NCBI Bookshelf
2023年7月3日 · Mechanism of Action. Tumor necrosis factor (TNF) plays a central role in the pathogenesis of several inflammatory conditions, including rheumatoid arthritis (RA). TNF is made intracellularly, mainly by activated macrophages. The precursor TNF is converted to soluble TNF after proteolysis by the TNF-converting enzyme.
Drug focus: adalimumab in the treatment of moderate to severe …
Adalimumab is a fully human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor (TNF)-alpha, and is administered by subcutaneous injection. The mechanism of action is based on both the neutralization of TNF-alpha bioactivity ...
Adalimumab: Dosage, Mechanism/Onset of Action, Half-Life
2020年2月17日 · Mechanism of Action. Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNFα receptor sites and subsequent cytokine-driven inflammatory processes.
Adalimumab - Nature Reviews Drug Discovery
2003年9月1日 · Adalimumab works by binding to TNF-α and blocking its interaction with the TNF receptor. The antibody can also lyse TNF-expressing cells in the presence of complement.
Adalimumab for the treatment of immune-mediated diseases: an ... - PubMed
Adalimumab is a fully recombinant human immunoglobulin G1 monoclonal antibody that specifically binds with high affinity to human TNF-α and inhibits its binding to TNF receptors.